Health
Maker seeking Indian trial of Novavax jab – 7NEWS.com.au
Vaccine maker, the Serum Institute of India, wants to trial the Novavax jab locally, to factor in genetic differences in its population.
The Serum Institute of India, the world’s biggest vaccine maker, has applied to local authorities to conduct a small domestic trial of Novavax Inc’s COVID-19 vaccine, which was found to be 89.3 per cent effective in a UK trial.
Serum expected a decision on an Indian trial of Novavax’s vaccine soon, Chief Executive Adar Poonawalla told Reuters on Friday, hours after the US company reported the efficacy data.
“We have already applied to the drug controller’s office for the bridging trial, a few days…
-
General15 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Noosa News17 hours agoSurgeon partner of former premier to testify over his patient’s death
-
Business15 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General16 hours agoToo skewed, too gentlemanly | The Spectator Australia